One of six promising orphan Drugs currently under development in Israel, AB103 was granted Fast Track and Orphan Drug designations by the FDA.
Drug developer Atox Bio announced today that the US Food and Drug Administration (FDA) has granted fast track designation to AB103, its lead product, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI).
Hebrew U. medical researchers find a tiny peptide encoded by the HIV virus could hold the key to making cancer therapies more successful.
Novel biocontrol agent is environmentally-friendly, non-toxic and effective for a large variety of plants
The novel method uses a peptide derived from HIV to increase the sensitivity of cancer cells to radiotherapy and chemotherapy
When Scientific American recently wrote about the progress in artificial intelligence, it profiled two IBM supercomputers: Deep Blue, which defeated the world champion Gary Kasparov in chess, and the Jeopardy-winning Watson. The other company it profiled is the little-known Mobileye, an Israeli firm whose strength lies in EyeQ, a chip with a dimension of only one square centimeter.
Montreal venture capitalist Matthew Price-Gallagher is bullish on Israel. The successful high-tech entrepreneur has been to the country about 20 times in the last two years, attracted to its refreshing “can-do” approach to business – and science.
Price-Gallagher, president and CEO of Water Cluster Scientific Inc., is collaborating with the Hebrew University of Jerusalem and its affiliated technology transfer company, Yissum, on research and development.
Five researchers at the Hebrew University's Faculty of Agriculture reach commercial success through Yissum, the university's technology transfer company.
The Hebrew University of Jerusalem (HUJ) recently unveiled "Innovators Way," a permanent photo exhibition showcasing 27 university researchers whose genius is behind commercial products that have revolutionized the fields of health, safety, environment, agriculture, computer science and nutrition.
Innovators Way celebrates the researchers whose creative concepts reached an advanced enough stage to allow Yissum Research Development, the university’s technology transfer company, to patent, commercialize and market their inventions to Israeli and international companies.
The agreement on behalf of the institute was made through Yissum, the technology transfer company of the Hebrew University. The program is designed to fund promising research that can lead to creating improved new health-care products, with the goal of having teams apply for follow-on funding through Drexel’s Coulter Translational Research Partnership program endowment or from other sources of translational research funding.
Experimental work by a Hebrew University researcher involving stimulation of a cannabinoid receptor in the immune system has been shown to hold promise for the treatment of many neurological, inflammatory and other illnesses.
Yissum Technology Transfer Company of the Hebrew University of Jerusalem president and CEO Yaacov Michlin added that this activity creates high-quality jobs. He estimated that each $1 million in exports creates 15 jobs.
Five young researchers from the Hebrew University of Jerusalem will receive Kaye Innovation Awards on Wednesday for their research into type 1 diabetes, anti-inflammatory drugs, increasing wheat yields, activation of cannabinoid receptors in the immune system and treatment to halt over-immune responses.
Israeli researchers from the Hebrew University of Jerusalem developed a new method to treat cancer with a different deadly disease: AIDS.
Prof. Kotler’s method has been recently registered as a patent by Yissum, the technology transfer company of the Hebrew University. Currently, the company is trying to find investors for the ongoing development of the product and its commercialization in the future.
Intel Corp is launching research in Israel into technology that mimics the human brain and develops devices that "learn" about their user. The research, to be carried out by the Intel Collaborative Research Institute for Computational Intelligence along with specialists from the Technion in Haifa and the Hebrew University in Jerusalem, is aimed at enabling new applications, such as small, wearable computers that can enhance daily life.
Merck announced today that within the scope of a capital increase by the Israeli start-up company QLight Nanotech, it is acquiring an interest in the Jerusalem-based company.
We are delighted to announce the first annual conference of the Israel Tech Transfer Organization (ITTN), to be held on June 11, 2012, at the Hilton hotel in Tel Aviv with the collaboration of the 12 technology transfer companies of the universities and leading hospitals and research institutes in Israel. The conference will showcase the unprecedented achievements of the Israeli tech transfer industry, and its contribution to the advancement of the Israeli economy through translating breakthrough inventions and technologies into commercial accomplishments.
Technology, to be presented at Agritech Israel 2012, enables better control over fish reproduction cycle, increasing spawning and fish size
New Hebrew University portrait exhibition spotlights the researchers whose bright ideas led to global products to improve quality of life. “If Israel is the start-up nation, then the Hebrew University is the start-up of the start-up nation,” said Hebrew University president Prof. Menahem Ben-Sasson at the opening. “So far, the university [through its tech-transfer company Yissum Research Development] has registered approximately 7,000 patents protecting roughly 2,000 developments and inventions, and founded 72 companies based on some of those inventions.”
Morflora, focused on innovative non-transgenic trait delivery technology for plant protection and enhancement, announced today it has been selected as a Finalist for Red Herring's Top 100 Europe award, a prestigious list honoring the year’s most promising private technology ventures from the European business region.